The Committee on Energy and Commerce is the oldest standing legislative committee (established 1795) in the U.S. House of Representatives and is vested with the broadest jurisdiction of any congressional authorizing committee. The Energy and Commerce Committee is at the forefront of all issues and policies powering America’s economy, including our global competitive edge in energy, technology, and health care. The committee is led by E&C Chairman Brett Guthrie (KY-02) and E&C Ranking Member Frank Pallone (NJ-06). The Subcommittee on Environment is led by Chairman Morgan Griffith (VA-09) and Ranking Member Paul Tonko (NY-20).
Today we welcome Secretary Kennedy to discuss the President's fiscal year
2027 budget for the Department of Health and Human Services. Mr. Secretary,
thank you for being here and for your continued engagement with this committee. At the outset,
I want to recognize the leadership of President Trump and your work at HHS to advance a bold
vision for Make America Healthy Again. The mission of HHS to promote and protect the health and
well-being of Americans has never been more important, especially as we confront rising
chronic disease, increasing health care costs, and growing access challenges across the country.
As a pharmacist, I've seen firsthand how these challenges play out in real life at the pharmacy
counter, in rural communities, and for patients trying to navigate a system that is often too
complicated and too expensive. Too often, patients walk away from needed care not because it isn't
available, but because they can't afford it, or because the system makes it too difficult to get
the care they need. And that's why I appreciate the administration's focus on prevention and
transparency and accountability. These are core principles that are reflected throughout this
budget. Efforts to strengthen primary care, expand behavioral health services, and invest in maternal
and child health are important steps toward improving outcomes and bending the cost curve
over time. A stronger emphasis on prevention, particularly addressing nutrition and chronic
disease, has the potential to reduce long-term costs while improving quality of life for millions
of Americans. I'm also encouraged by the emphasis on health care affordability. Families in East
Tennessee where I'm from and across the country continue to feel the strain of high drug pricing,
rising premiums, and out-of-pocket costs. The administration's work to increase price transparency
and ensure patients have access to clear, usable pricing information is a critical step toward
restoring a functioning health care marketplace. Similarly, efforts to promote competition through
biosimilars and streamline regulatory pathways can help bring down costs and expand treatment
options. And modernizing tools like prior authorization to reduce delays and administrative
burden is something both patients and providers have long asked for and have long needed.
Another area of strong interest for this subcommittee, and certainly for my district,
is rural health. We know that rural communities face unique challenges, including provider
shortages, hospital closures, and limited access to specialty care. In many parts of my district,
patients have to travel long distances just to see a provider or fill a prescription.
I look forward to hearing more about how this budget supports rural providers,
strengthens the health care workforce, and ensures that patients, regardless of where they live,
can access timely, high-quality care. Investments in primary care, workforce development,
and community-based services will be key to stabilizing rural health systems and providing
outcomes. I also want to commend the department's focus on program integrity and stewardship of
taxpayer dollars. Efforts to combat fraud, waste, and abuse in Medicare and Medicaid and to move
toward real-time oversight are essential to protecting these programs for the patients
who depend on them. Every dollar lost to fraud is a dollar that cannot be used for patient care,
and strong oversight is critical to maintaining trust in our health care system.
Finally, I want to highlight the importance of ensuring patients have access to innovative
treatments and therapies, the administration's effort to accelerate drug development,
reduce unnecessary regulatory barriers, and support individualized therapies,
particularly for rare diseases, are promising steps forward. At the same time, we must ensure
that these scientific advancements translate into real-world access, so patients can get
the care they need, when they need it, without unnecessary delay. Mr. Secretary, this budget
outlines an ambitious agenda to improve health outcomes, modernize federal programs, and make
health care more affordable and accessible. This subcommittee looks forward to working with you to
ensure these priorities are implemented in a way that delivers real results for real American
people. And I appreciate your testimony, and I look forward to our discussion today, sir.